<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">C. Dirk Keene</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Washington</td>
</tr>
<tr>
<td class="label">Country</td>
<td>United States</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Alzheimer's Disease, Neurofibrillary Tangles</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Neurofibrillary Tangles, Cell Type Diversity, PET-Autopsy Correlation</td>
</tr>
</table>
C. Dirk Keene
Overview
C. Dirk Keene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
C. Dirk Keene is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Washington. Their work focuses on Neuropathology, brain atlases, PET-autopsy correlation, mixed pathologies, single-nucleus RNA sequencing, contributing significantly to our understanding of disease mechanisms and diagnostic approaches.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease), [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
Mechanisms of Interest
- Neurofibrillary Tangles, Cell Type Diversity, PET-Autopsy Correlation
Key Publications
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">C. Dirk Keene</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Washington</td>
</tr>
<tr>
<td class="label">Country</td>
<td>United States</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Alzheimer's Disease, Neurofibrillary Tangles</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Neurofibrillary Tangles, Cell Type Diversity, PET-Autopsy Correlation</td>
</tr>
</table>
C. Dirk Keene
Overview
C. Dirk Keene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
C. Dirk Keene is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Washington. Their work focuses on Neuropathology, brain atlases, PET-autopsy correlation, mixed pathologies, single-nucleus RNA sequencing, contributing significantly to our understanding of disease mechanisms and diagnostic approaches.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease), [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
Mechanisms of Interest
- Neurofibrillary Tangles, Cell Type Diversity, PET-Autopsy Correlation
Key Publications
2023. Transcriptomic diversity of cell types across the adult human brain. [DOI:10.1101/2022.10.12.511898](https://doi.org/10.1101/2022.10.12.511898)
2017. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. [DOI:10.1016/j.jalz.2016.09.015](https://doi.org/10.1016/j.jalz.2016.09.015)
2020. Comparison of regional flortaucipir PET with quantitative [tau](/proteins/tau) immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. [DOI:10.1186/s13550-020-00653-x](https://doi.org/10.1186/s13550-020-00653-x)
Collaborations
Dr. Keene has established significant collaborations across multiple research consortia. He is a key contributor to the Seattle Alzheimer's Disease Brain Cell Atlas (SEA-AD) project, which aims to create a comprehensive molecular map of the Alzheimer's disease brain. His work with the National Alzheimer's Coordinating Center (NACC) has advanced understanding of mixed pathologies in aging and dementia. These collaborations have enabled integration of neuropathological data with clinical trajectories.
Training and Mentorship
At the University of Washington, Dr. Keene has trained numerous researchers in neuropathology techniques and single-cell genomics approaches. His mentorship program emphasizes rigorous morphological assessment combined with modern molecular methods, producing researchers who are well-versed in both traditional neuropathology and cutting-edge transcriptomics.
Impact
Dr. Keene's work on PET-autopsy correlation has been critical for validating in vivo imaging biomarkers. His research on mixed pathologies has revealed that most dementia cases involve multiple underlying diseases, challenging the simple amyloid-tau model and informing more accurate diagnostic and therapeutic approaches.
Future Directions
Ongoing work includes:
- Single-nucleus RNA sequencing to map cell-type-specific changes in Alzheimer's disease
- Integration of multimodal data for improved pathological characterization
- Development of next-generation brain atlases with molecular annotations
- Translation of molecular findings to clinical applications
Recent Research
Recent PubMed-indexed publications (2024-present):
[A roadmap to human hippocampal neurogenesis in adulthood, aging and AD](https://pubmed.ncbi.nlm.nih.gov/38854131/). Research square. 2024.
See Also
- [University of Washington](/university-of-washington)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neuroimaging](/mechanisms/neuroimaging-methodology)
- [PET Imaging](/mechanisms/pet-imaging)
External Links
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=C.+Dirk+Keene)
His research on the Seattle Alzheimer's Disease Brain Cell Atlas represents a major advance in understanding the cellular and molecular basis of Alzheimer's disease. By combining single-nucleus RNA sequencing with detailed neuropathological assessment, the project has generated unprecedented insights into how different cell types in the brain are affected by Alzheimer's disease pathology. This work has identified specific cell type vulnerabilities, novel subpopulations of [neurons](/entities/neurons) and glia, and molecular pathways that could be targeted for therapeutic intervention.
Dr. Keene's contributions to neuropathology methodology have been significant. He has developed standardized protocols for tissue processing, immunohistochemistry, and pathological assessment that are now used internationally. His work on the quantification of tau pathology using automated image analysis has improved the precision and reproducibility of neuropathological research. These methodological advances have accelerated the pace of discovery in the field and have facilitated comparisons across studies.
The translational impact of Dr. Keene's research is substantial. By establishing rigorous validation methods for PET imaging ligands, his work has enabled the use of tau PET scans as biomarkers in clinical trials. This has been crucial for developing disease-modifying therapies and for monitoring treatment response. His research on mixed pathologies has also informed clinical practice guidelines for dementia diagnosis, emphasizing the importance of comprehensive neuropathological assessment.
Overview
C. Dirk Keene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of C. Dirk Keene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Research Contributions
Mermaid diagram (expand to render)
References
[Unknown, 2023. Transcriptomic diversity of cell types across the adult human brain (2023)](https://doi.org/10.1101/2022.10.12.511898)
[Unknown, 2017. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample (2017)](https://doi.org/10.1016/j.jalz.2016.09.015)
[Unknown, 2020. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study (2020)](https://doi.org/10.1186/s13550-020-00653-x)